TABLE 3.
Group | MTL | ET‐1 | VIP | AchE | Gastrin | SP | SS |
---|---|---|---|---|---|---|---|
Normal | 192.5 ± 13.5a | 13.3 ± 1.6e | 80.4 ± 7.7a | 50.9 ± 15.7a | 90.6 ± 5.9a | 71.5 ± 4.3a | 28.3 ± 1.6d |
Model | 92.7 ± 13.7e | 31.0 ± 6.4a | 38.4 ± 3.1e | 16.9 ± 5.8d | 41.5 ± 2.7e | 33.6 ± 2.2e | 61.5 ± 6.3a |
LP‐KSFY06 | 127.7 ± 8.9d | 24.8 ± 2.7b | 49.1 ± 2.8d | 28.5 ± 3.0c | 45.6 ± 4.3d | 43.5 ± 1.8d | 48.1 ± 1.6b |
Geniposide | 143.6 ± 6.9c | 18.8 ± 1.5c | 54.6 ± 4.8c | 37.6 ± 5.0b | 65.2 ± 3.8c | 54.3 ± 4.6c | 41.4 ± 1.9c |
LP + G | 167.8 ± 14.8b | 16.1 ± 3.2d | 70.5 ± 4.9b | 45.3 ± 6.1a | 73.0 ± 4.6b | 61.0 ± 4.8b | 35.2 ± 2.9d |
Values presented are the mean ± standard deviation (n = 10/group).
Day 1–6: treatment period without induction of constipation; Day 7–9: treatment period with induction of constipation.
LP‐KSFY06: mice treated with 0.5 × 107 CFU/kg of Lactobacillus plantarum KSFY06; Geniposide: mice treated with 50 mg/kg body weight of geniposide; LP + G: mice treated with 1.0 × 107 CFU/kg of Lactobacillus plantarum KSFY06 and 50 mg/kg body weight of geniposide.
Abbreviations: AChE, acetylcholinesterase; ET‐1, endothelin‐1; MTL, motilin; SP, substance P; SS, somatostatin; VIP, vasoactive intestinal peptide.
a‐eIn the same column means significant differences (p < .05) according to Duncan's multiple range test.